Biotechnology company developing Deep Screening, a proprietary platform that experimentally collects sequence and functional data from hundreds of millions of biologics to identify therapeutic candidates and generate datasets for AI-assisted biologics discovery and engineering
Biotechnology company developing Deep Screening, a proprietary platform that experimentally collects sequence and functional data from hundreds of millions of biologics to identify therapeutic candidates and generate datasets for AI-assisted biologics discovery and engineering. Its platform targets complex antibody and other biologic design challenges, including novel, switchable, and conditional therapeutics.